Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploring the Use of Remimazolam (BYFAVO®) in Patients at High Risk for ERCP to Reduce Intraoperative Hypotension and Assess Safety and Efficacy: A Randomized Controlled Trial

NCT06258356 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT06258356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06258356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploring the Use of Remimazolam (BYFAVO®) in Patients at High Risk for ERCP to Reduce Intraoperative Hypotension and Assess Safety and Efficacy: A Randomized Controlled Trial
Lead sponsor
National Taiwan University Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
February 15, 2024
Completion date
December 31, 2030
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

the severity and duration of intraoperative hypotension